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Abstract
Background: Elevated circulating levels of several inflammatory biomarkers have been described in selected patient 
populations with COPD, although less is known about their population-based distribution. The aims of this study were 
to compare the levels of several systemic biomarkers between stable COPD patients and healthy subjects from a 
population-based sample, and to assess their distribution according to clinical variables.
Methods: This is a cross-sectional study design of participants in the EPI-SCAN study (40-80 years of age). Subjects with 
any other condition associated with an inflammatory process were excluded. COPD was defined as a post-
bronchodilator FEV1/FVC < 0.70. The reference group was made of non-COPD subjects without respiratory symptoms, 
associated diseases or prescription of medication. Subjects were evaluated with quality-of-life questionnaires, 
spirometry and 6-minute walk tests. Serum C-reactive protein (CRP), tumor necrosis factor (TNF)-α, interleukins (IL-6 
and IL-8), alpha1-antitrypsin, fibrinogen, albumin and nitrites/nitrates (NOx) were measured.
Results: We compared 324 COPD patients and 110 reference subjects. After adjusting for gender, age, BMI and tobacco 
consumption, COPD patients showed higher levels of CRP (0.477 ± 0.023 vs. 0.376 ± 0.041 log mg/L, p = 0.049), TNF-α 
(13.12 ± 0.59 vs. 10.47 ± 1.06 pg/mL, p = 0.033), IL-8 (7.56 ± 0.63 vs. 3.57 ± 1.13 pg/ml; p = 0.033) and NOx (1.42 ± 0.01 
vs. 1.36 ± 0.02 log nmol/l; p = 0.048) than controls. In COPD patients, serum concentrations of some biomarkers were 
related to severity and their exercise tolerance was related to serum concentrations of CRP, IL-6, IL-8, fibrinogen and 
albumin.
Conclusions: Our results provide population-based evidence that COPD is independently associated with low-grade 
systemic inflammation, with a different inflammatory pattern than that observed in healthy subjects.
Background
Chronic obstructive pulmonary disease (COPD) is asso-
ciated with important extrapulmonary manifestations,
including weight loss, skeletal muscle dysfunction, car-
diovascular disease, depression, osteoporosis, reduced
exercise tolerance, and poor health status [1,2]. Although
the pathobiologyof COPD has not been fully determined,
systemic inflammation has been implicated in the patho-
genesis of the majority of these systemic effects [3], to the
point that some authors have suggested that COPD is a
part of a chronic systemic inflammatory syndrome [4].
The association between systemic inflammation and
COPD has mostly been evaluated in highly selected
patient samples, which have shown activation of circulat-
ing inflammatory cells and increased levels of proinflam-
matory cytokines and acute-phase reactants as well as
increased oxidative stress [5-7]. The limitations derived
from the small size and partial scope of most of these
studies led to the completion of a meta-analysis, which
compiled the main current evidence supporting the pres-
ence of systemic inflammation in stable COPD patients
[8]. Nevertheless, there were remarkable differences in
the selection of subjects and the definitions of COPD
employees were neither homogeneous nor adapted to
current guidelines [9]. In the population-based studies
included in this analysis, COPD diagnosis was assumed
in participants in the lowest quartile of predicted FEV1,
and those subjects in the highest quartile of predicted
FEV1 were taken as controls. The controversy has been
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reinforced by another recent meta-analysis that did not
find statistically significant differences in either serum C-
reactive protein (CRP) or tumour necrosis factor (TNF)-
α concentrations between healthy subject groups and any
of the COPD stages [10].
In contrast, an inverse association between higher lev-
els of circulating inflammation-sensitive proteins, includ-
ing CRP, interleukin (IL)-6 and alpha-1 antitrypsin
(A1AT), and lower spirometric values has been described
in several samples of middle-aged to older general popu-
lation [11-13]. Moreover, it has recently been reported
that increased serum levels of CRP are associated with an
increase risk of developing COPD in a population-based
sample of smokers [14].
In the population-based Epidemiologic Study of COPD
in Spain (EPI-SCAN) we have compared serum levels of
several biomarkers between stable COPD patients and
healthy subjects trying to analyse the contribution of pos-
sible confounding factors to the development of systemic
inflammation. We selected the following biomarkers:
CRP, TNF-α, IL-6, IL-8, alpha-1 antitrypsin (A1AT),
fibrinogen, albumin and nitrites/nitrates (NOx), because
they have been more widely studied in COPD and they
have shown some relationship with either its prognosis
and/or the development of cardiovascular complications.
We have also evaluated the relation between systemic
biomarkers and pulmonary function, exercise tolerance
and health-related quality of life in COPD patients
derived from the general population.
Methods
Study design and participants
The present study is part of the EPI-SCAN study, a multi-
centre, cross-sectional, population-based, observational
study conducted at 11 sites throughout Spain [15,16]. The
final population recruited was formed by 4,274 non-insti-
tutionalized participants from 40-80 years old. The study
was approved by the corresponding ethics committees
and all participants gave written informed consent.
In accordance with current GOLD guidelines, COPD
was defined by a postbronchodilator FEV1/FVC ratio <
0.70 [9]. COPD severity was determined by the GOLD
criteria and the BODE index [9,17]. Subjects with a post-
bronchodilator FEV1/FVC ratio ≥ 0.70 were considered
not to have COPD.
All participants classified as COPD were selected for
the systemic biomarker analysis. To avoid excessive test-
ing of the non-COPD study population, an equal number
of non-COPD subjects were consecutively selected in
each centre. Exclusion criteria for this analysis included a
previous diagnosis of acute myocardial infarction, angina,
congestive heart failure, cancer, hepatic cirrhosis, chronic
renal failure, rheumatoid arthritis or any other systemic
inflammatory disease. In addition, specific exclusion cri-
teria from the non-COPD cohort were any respiratory
symptoms as per the European Coal and Steel Commu-
nity (ECSC) questionnaire, any associated concomitant
disease, and regularly prescribed medications. The refer-
ence group obtained after applying these selection crite-
ria was considered to be of healthy subjects.
Procedures
Fieldwork and all methods have been described previ-
ously [15,16]. Self-reported exposure was identified ini-
tially through a questiondeveloped for the European
Community Respiratory Health Survey: "Have you ever
worked in a job which exposed you to vapors, gas, dust,
or fumes?" The question was followedby a list of 23 indi-
vidual exposures considered a priori risk factors for
COPD, subsequently grouped into three categories: bio-
logical dusts, mineral dusts and gases or fumes. Baseline
dyspnea was assessed by the Modified Medical Research
Council (MMRC) scale, and subjects completed the
ECSC questionnaire of respiratory symptoms, the Lon-
don Chest Activity of Daily Living (LCADL) scale, the
EQ-5D questionnaire and the St. George's Respiratory
Questionnaire.
Blood samples were collected using standardized pro-
cedures and stored at -80°C. Samples were shipped to a
single laboratory (Hospital Clinic, Barcelona) for central-
ized analysis approximately every 2 months. TNF-α, IL-6
and IL-8 were determined in duplicate with a high sensi-
tivity enzyme-linked immunosorbent assay (Biosource,
Nivelles, Belgium) with lower detection limits of 3 pg/ml
for total TNF-α, 2 pg/ml for IL-6 and 0.7 pg/ml for IL-8.
The intra-assay coefficients of variation were 3.7% for
TNF-α, 2.2% for IL-6 and 2.3% for IL-8. C-reactive pro-
tein (CRP) was assessed by latex-enhanced immunon-
ephelometry (Siemens, Dublin, Ireland) with a lower
detection limit of 0.4 mg/l and an intra-assay coefficient
of variation of 1.2%. Alpha-1 antitrypsin (A1AT) was
measured by a particle-enhanced immunonephelometry
(Siemens, Malburg, Germany), with detection limits
ranged from 0.0095 to 0.3040 g/l and an intra- and inter-
assay variability or 3.9% and 2.0%, respectively.
Albumin levels were estimated by the bromocresol
green method (Siemens, Dublin, Ireland), with a detec-
tion limits from 10 to 60 g/l and an intra-assay coefficient
of variation of 1.5%. Fibrinogen was assessed using a
coagulation analyzer (Roche, Mannheim, Germany)
according to the Clauss method and calculated from eth-
ylenediamine tetra-acetic acid to citrate plasma values.
The detection range was 0.5 to 12.0 g/L and the intra-
assay variability 2.8%. Nitrites and nitrates (NOx) were
determined by a chemiluminescence detector in an NO
analyser (Sievers Instruments, Inc., Boulder, CO, USA).
The lower detection limit was 1 pmol and the intra-assay
coefficient of variation was 10%.Garcia-Rio et al. Respiratory Research 2010, 11:63
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Baseline and post-bronchodilator spirometries were
performed at each site using the same equipment accord-
ing to current recommendations [18]. The predicted val-
ues used were those of the Spanish reference population
[19]. A 6-min walk test was performed twice, with an
interval between testing of 30 minutes, according to the
ATS guidelines [20].
Analysis
Variables are presented as a percentage, mean ± SD or
median (interquartile range) as required depending on
their distribution. Statistical analysis was performed with
SPSS 14.0 for Windows (SPSS, Inc., Chicago, IL) and with
SAS statistical package (version 9.1, Cary, NC). A two-
sided p value < 0.05 was considered statistically signifi-
cant.
Pearson's chi-square test, Mann-Whitney U test or Stu-
d e n t ' s  t  t e s t  w e r e  u s e d  f o r  t w o - g r o u p  c o m p a r i s o n s ,
depending on data distribution. The effect of the possible
confounding factors was assessed using generalised linear
model analysis [21]. In this analysis, a logarithmic trans-
formation was used in those variables to reduce their
skewness. We constructed a multivariate model, includ-
ing group and gender as fixed factors and age, BMI and
smoking history as a dichotomous variable (≥ 10 pack-
years, yes/no) as covariates. The link function used was
the identity. For each systemic biomarker, we chose the
normal distribution because it was more fitting than
inverse Gaussian or gamma distribution, according to the
plausibility criteria, Pearson's chi-square and analysis of
deviance. Comparisons by differing severity within the
COPD group were performed using ANOVA analysis,
with post-hoc analysis by the Bonferroni test. In the
COPD group, the correlations between the serum levels
of systemic biomarkers and the clinical and functional
parameters were estimated using Pearson's linear bivari-
ate correlation coefficient.
Data are presented according to current recommenda-
tions for observational studies in epidemiology
(STROBE).
Results
A total of 3,802 subjects were evaluated. From 386 sub-
jects identified with COPD according to GOLD, 12
refused blood extraction and 50 were excluded due to evi-
dence of comorbidity, leaving 324 subjects in the COPD
group for analysis. Of 373 consecutively-selected subjects
without COPD, 250 were excluded due to respiratory
symptoms and 13 for evidence of comorbidity, rendering
110 subjects in the control group (Figure 1).
Participant characteristics are described in Table 1. In
comparison with the reference group, there were more
men and smokers, of greater smoking intensity, who were
older, with higher body mass index in the COPD group.
There was a wide range of COPD severity in our cohort,
although only 23% of these patients were taking inhaled
corticosteroids. Table 2 shows the occupational exposure
characteristics of the patients included in the COPD
group.
The crude comparison of serum level biomarkers
showed that COPD participants had higher concentra-
tions of CRP, TNF-α, IL-6, IL-8, alpha-1 antitrypsin,
fibrinogen and nitrites/nitrates than control subjects
(Figure 2). On the contrary, albumin concentration was
non-significantly decreased (p = 0.061).
Table 3 shows the estimates obtained from generalized
linear models with gender, age, BMI, pack-years and
group as dependent variables. After adjusting for these
covariates, group dependence was retained for CRP,
TNF-α, IL-8 and nitrites/nitrates, with a positive effect
on their serum concentrations. After adjustment for gen-
der, age, BMI and pack-years, COPD participants pre-
sented higher levels of log CRP (mean ± mean standard
error) (0.477 ± 0.023 vs. 0.376 ± 0.041 log mg/L, p =
0.049), TNF-α(13.12 ± 0.59 vs. 10.47 ± 1.06 pg/mL, p =
0.033), IL-8 (7.56 ± 0.63 vs. 3.57 ± 1.13 pg/ml; p = 0.033)
and nitrites/nitrates (1.42 ± 0.01 vs. 1.36 ± 0.02 log nmol/
l; p = 0.048). No differences for adjusted levels of alpha-1
antitrypsin, IL-6, fibrinogen or albumin were found
between COPD and reference subjects (Figure 3).
Serum concentrations of several systemic biomarkers
were mostly higher in severe COPD than in moderate or
mild COPD. Of interest, these differences with biomarker
concentrations were not concordant with severity
assessed by GOLD and the BODE index (Tables 4 and 5),
and the biomarkers most consistent for the severity dis-
crimination were CRP, IL-6 and nitrites/nitrates.
In COPD participants, a relationship between systemic
biomarker concentrations and health status scores was
found. Dyspnea intensity, assessed by the MMRC, was
weakly related to CRP (r = 0.133, p = 0.027) and to fibrin-
ogen concentrations (r = 0.131, p = 0.021). A weak rela-
tionship between the symptoms domain of the SGRQ and
the IL-8 serum concentration was noted (r = 0.112, p =
0.049), while the activity domain was related with CRP (r
= 0.164, p = 0.006), IL-6 (r = 0.117, p = 0.039), fibrinogen
(r = 0.158, p = 0.006) and albumin (r = -0.140, p = 0.014).
Indeed, CRP level was also weakly related to the visual
analogue scale score (r = -0.146, p = 0.015) and utility
score in the EQ-5D (r = -0.121, p = 0.045). Biomarker
serum concentrations also showed a weak relationship
with the functional characteristics of COPD patients.
Post-bronchodilator FEV1 was inversely related to CRP (r
= -0.142, p = 0.018) and to IL-6 (r = -0.190, p = 0.023). In
the same way, we found a weak relationship between
exercise tolerance and serum concentrations of CRP (r = -
0.167, p = 0.007), IL-6 (r = -0.174, p = 0.003), IL-8 (r = -Garcia-Rio et al. Respiratory Research 2010, 11:63
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Figure 1 Flow-chart for the constitution of study groups.
Subjects randomly contacted
(n=4,274)
Subjects evaluated
(n=3,802)
Refused participation (n=389)
Non-evaluable subjects (n=83)
COPD subjects
(n=386)
Non-COPD subjects
(n=3,416)
Non-COPD subjects
with blood sample
(n=373)
Refused 
extraction (n=12)
consecutive selection
Reference group
(n=110)
Comorbidity (n=50)
- Ischemic cardiac disease (n=11)
- Chronic heart failure (n=10)
- Connective tissue disease (n=2)
- Hepatic disease/cirrhosis (n=2)
- Diabetes mellitus (n=12)
- Renal disease (n=2)
- Neoplasia (n=11)
COPD group
(n=324)
Respiratory symptoms (n=250)
- Chronic cough (n=47)
- Chronic mucus production (n=40)
- Dyspnoea (n=39)
- Wheezing (n=126)
- Bronchospasm (n=107)
- Asthma (n=29)
- Chronic bronchitis (n=18)
Comorbidity (n=13)
- Peripheral vascular disease (n=3)
- Cerebrovascular disease (n=1)
- Connective tissue disease (n=5)
-U l c u s( n = 5 )
- Hepatic disease/cirrhosis (n=2)
- Diabetes mellitus (n=7)
- Renal disease (n=1)
- Neoplasia (n=3)Garcia-Rio et al. Respiratory Research 2010, 11:63
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Table 1: General characteristics of the study groups.
COPD group
(n = 324)
Reference group
(n = 110)
p
Male gender 241 (74%) 51 (46%) < 0.0001
Age (years) 64 (10) 55 (10) 0.0001
Smoking status < 0.0001
Never smoker 67 (21%) 66 (60%)
Former smoker 138 (43%) 30 (27%)
Current smoker 119 (37%) 14 (13%)
Smoking exposure (pack-years) 40 (25-55) 10 (5-30) < 0.0001
Body mass index (Kg/m2) 27.9 (4.8) 26.1 (3.4) 0.001
Education level 0.130
Less than primary school 53 (16%) 9 (8%)
Primary school 120 (37%) 41 (37%)
Secondary school 84 (26%) 40 (36%)
University degree 62 (19%) 20 (18%)
Current treatment
Short-acting beta-agonist 57 (18%) 0 0.0001
Long-acting beta-agonist 68 (21%) 0 0.0001
Anticholinergic 52 (16%) 0 0.0001
Methylxantines 7 (2%) 0 0.127
Inhaled corticosteroids 75 (23%) 0 0.0001
Pulmonary function
FVC (L) 3.34 (1.00) 3.96 (1.12) < 0.0001
FVC (% of predicted) 99 (22) 119 (16) < 0.0001
FEV1 (L) 2.03 (0.67) 3.13 (0.88) < 0.0001
FEV1 (% of predicted) 77 (19) 115 (15) < 0.0001
FEV1/FVC 0.61 (0.08) 0.79 (0.05) < 0.0001
Postbronchodilator FVC (L) 3.53 (1.01) 3.95 (1.10) < 0.0001
Postbronchodilator FVC (% of predicted) 105 (21) 119 (14) < 0.0001
Postbronchodilator FEV1 (L) 2.18 (0.69) 3.19 (0.88) < 0.0001
Postbronchodilator FEV1 (% of predicted) 82 (20) 117 (14) < 0.0001
Postbronchodilator FEV1/FVC 0.62 (0.08) 0.81 (0.05) < 0.0001
Distance walked in 6 minutes (m) 450 (122) 514 (108) < 0.0001
BODE index score < 0.0001
Quartile 1 (0-2) 282 (90%) 110 (100%)
Quartile 2 (3-4) 19 (6%) 0
Quartile 3 (5-6) 10 (3%) 0
Quartile 4 (7-10) 2 (0.6%) 0Garcia-Rio et al. Respiratory Research 2010, 11:63
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0.137, p = 0.019), fibrinogen (r = -0.256, p < 0.001) and
albumin (r = 0.180, p = 0.002) (Figure 4).
Discussion
This study provides population-based evidence that sta-
ble COPD patients have a pro-inflammatory state, with
increased circulating levels of many inflammatory cytok-
ines and acute-phase reactants. In addition to the contri-
bution of previously-recognized factors such as age,
gender, BMI or smoking, COPD constitutes an indepen-
dent factor for the elevation of many of the analyzed sys-
temic biomarkers, which in the case of CRP, TNF-alpha,
IL-6 and NOx is also dependent on severity. Finally, base-
line inflammatory markers show a relation with some
domains of health-related quality of life, airflow limita-
tion and exercise tolerance.
Confounding factors
T o adequately evaluate the effect of COPD on systemic
biomarkers, several risk factors associated with COPD
should be considered. COPD is an age-related disorder
and the normal process of aging appears to be associated
with a similar low-grade systemic inflammatory process
[16,22]. The importance of gender is given by the fact that
females have a more vigorous inflammatory reaction and
generate more oxidative stress in the airways than males
[23]. Although an abnormal systemic inflammatory reac-
tion is detected in most smokers, it has been demon-
strated that some systemic biomarkers remain
persistently high after smoking cessation [24], suggesting
the contribution of other factors. For this reason, some
authors propose to evaluate the impact of tobacco on sys-
temic biomarkers depending on whether a dose threshold
(10 pack-years) has been reached [25]. Obesity is associ-
ated with low-grade systemic inflammation and it has
been suggested that the distribution of body compart-
ments might originate a different behaviour of some
inflammatory markers [26,27]. In concordance with pre-
vious reports [28], a direct correlation was found between
BMI and CRP (r = 0.242, p = 0.0001) in the COPD partic-
ipants of our study.
Systemic biomarkers in COPD
After adjusting for possible confounding factors, we
report that COPD patients showed higher levels of TNF-
α, IL-6, IL-8, CRP and nitrites/nitrates than control sub-
jects. The origin of systemic inflammation in COPD is
not completely clear. The hypothesis that systemic
inflammation is originated by spill over from the pulmo-
nary compartment has not yet been proven [3]. It has
been suggested that some common genetic or constitu-
tional factors may predispose individuals with COPD
EQ-5D questionnaire
VAS score 75 (60-85) 85 (80.0-93.8) < 0.0001
Utility score 0.91 (0.83-1.0) 1.0 (1.0-1.0) < 0.0001
SGRQ
Total 16.7 (6.2-28.6) 1.3 (0.0-3.3) < 0.0001
Symptoms 19.6 (8.8-41.2) 4.3 (0.0-9.5) < 0.0001
Activity 23.6 (6.0-47.7) 0.0 (0.0-0.0) < 0.0001
Impact 7.6 (1.6-19.5) 0.0 (0.0-0.0) < 0.0001
LCADL scale 15 (14-17) 15 (15-15) 0.003
Values are mean (SD) or median (interquartile range) depending on the distribution. Abbreviations: FVC = forced vital capacity; FEV1= forced 
expiratory volume in 1 second; SGRQ = St George Respiratory Questionnaire; LCADL = London Chest Activity of Daily Living. Comparisons 
between groups by U-Mann-Whitney test or t-Student test depending on the distribution.
Table 1: General characteristics of the study groups. (Continued)
Table 2: Occupational exposure characteristics of COPD patients by smoking status.
Never smoker Former smoker Current smoker p
Subjects, n 67 138 119
Self-reported exposure to vapors, gases, dusts or fumes Job exposure 27 (40.3%) 54 (39.1%) 49 (41.2%) 0.945
Biological dusts 15 (22.4%) 56 (40.6%) 50 (42.0%) 0.017
Mineral dusts 24 (35.8%) 48 (34.8%) 37 (31.1%) 0.752
Gases or fumes 33 (49.3%) 55 (39.9%) 48 (40.3%) 0.398
Comparisons between groups by chi-square testGarcia-Rio et al. Respiratory Research 2010, 11:63
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Figure 2 Box-and-whisker plots of the systemic biomarker crude distribution in COPD and reference groups. The top of the box represents 
the 75 th percentile, the bottom of the box represents the 25 th percentile, and the line in the middle represents the 50 th percentile. The whiskers 
represent the highest and lowest values that are not outliers or extreme values. Outliers (values that are between 1.5 and 3 times the interquartile 
range) and extreme values (values that are more than 3 times the interquartile range) are represented by circles and asterisks beyond the whiskers. 
Abbreviations: TNF = tumor necrosis factor; IL = interleukin. Comparisons between groups by U-Mann-Whitney test or t-Student test depending on 
the distribution.
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Table 3: Significance of each multivariate model to estimate systemic biomarkers*.
Biomarker Parameter Coefficient (SE) Wald 95% CI p-value
C-reactive protein† Intercept -0.44 (0.173) -0.785- -0.103 0.011
Age 0.005 (0.002) 0.001-0.009 0.012
BMI 0.019 (0.004) 0.011-0.028 0.001
Smoker 0.036 (0.155) -0.268-0.340 0.816
Gender -0.004 (0.044) -0.089-0.083 0.936
COPD group 0.101 (0.049) 0.004-0.198 0.041
TNF-alpha Intercept 6.306 (4.301) -2.151-14.763 0.143
Age 0.062 (0.049) -0.034-0.158 0.207
BMI 0.059 (0.110) -0.157-0.276 0.590
Smoker 0.810 (3.434) -5.942-7.562 0.814
Gender -0.989 (1.088) -3.128-1.150 0.364
COPD group 2.668 (1.250) 0.211-5.125 0.033
IL-6 Intercept 3.420 (2.477) -1.450-8.290 0.168
Age 0.025 (0.028) -0.030-0.081 0.367
BMI 0.017 (0.063) -0.108-0.142 0.787
Smoker -0.597 (1.934) -4.399-3.204 0.758
Gender -1.525 (0.619) -2.741- -0.309 0.014
COPD group 1.194 (0.713) -0.207-2.595 0.095
IL-8 Intercept 9.436 (4.712) 0.173-18.700 0.046
Age -0.007 (0.053) -0.112-0.098 0.892
BMI -0.214 (0.121) -0.451-0.024 0.078
Smoker 2.951 (3.672) -4.267-10.169 0.422
Gender 0.277 (1.175) -2.034-2.587 0.814
COPD group 3.995 (1.350) 1.342-6.648 0.003
Alpha-1 antitrypsin Intercept 1.307 (0.184) 0.947-1.668 < 0.001
Age 0.003 (0.002) -0.001-0.007 0.153
BMI 0.001 (0.005) -0.011-0.008 0.785
Smoker 0.069 (0.143) -0.351-0.213 0.630
Gender 0.003 (0.046) -0.087-0.093 0.945
COPD group 0.084 (0.053) -0.019-0.187 0.112
Fibrinogen Intercept 0.484 (0.416) -0.335-1.302 0.246
Age 0.030 (0.005) 0.020-0.039 0.001
BMI 0.021 (0.011) 0.000-0.042 0.050
Smoker -0.087 (0.325) -0.726-0.551 0.788
Gender 0.344 (0.104) 0.139-0.549 0.001
COPD group 0.134 (0.119) -0.100-0.369 0.260Garcia-Rio et al. Respiratory Research 2010, 11:63
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towards both systemic and pulmonary inflammation [29].
Lung hyperinflation, tissue hypoxia and skeletal muscle
and bone marrow alterations have also been implicated in
the induction of systemic inflammation [3].
A l t h o u g h  a n  i n c r e a s e d  p r o d u c t i o n  o f  N O  i n  C O P D
patients could constitute a host defense mechanism, a
high level of NO can also cause injury and thus contrib-
ute to the respiratory and systemic features of the disease.
In an inflammatory environment, exaggerated produc-
tion of NO in the presence of oxidative stress may pro-
duce the formation of strong oxidizing reactive nitrogen
species, such as peroxynitrite, leading to nitration, which
provokes inhibition of mitochondrial respiration, protein
dysfunction and cell damage [30]. The activation of vari-
ous heme peroxidases by hydrogen peroxide can promote
oxidation of nitrites to intermediates that are capable of
nitrating aromatic substratesand proteins [30].
Although the COPD severity classification according to
the BODE index shows a great capacity for discriminating
among the systemic biomarker levels, as expected from
its multicomponent character, the GOLD classification
also shows differences in biomarker levels. However, the
selection of a small number of severe patients in our pop-
ulation sample may reduce the strength of a possible
association between biomarkers and GOLD stage. In
some previous studies, the relation between plasma CRP
levels and the severity of the disease has already been
suggested [5,31]. De Torres and colleagues reported the
usefulness of CRP in predicting clinical and functional
outcomes in stable COPD, with similar correlation coeffi-
cients to those of our study [27].
Nevertheless, one of the major implications of systemic
inflammation in COPD is its contribution to a proathero-
sclerotic state. The relationship between COPD, systemic
inflammation, and cardiovascular diseases may be espe-
c i a l l y  r e l eva n t  a s  o v e r  h a l f  o f  p a t i e n t s  w i t h  C O P D  d i e
from cardiovascular causes [32]. A Copenhagen City
Heart Study cohort study showed that the incidence of
COPD hospitalization and COPD death was higher in
individuals with baseline CRP above 3 mg/L, with an
absolute 10-yr risk for death of 57% [33]. In fact, it has
been suggested that CRP can be considered as the senti-
nel biomarker [32,33]. Interesting, in our COPD patients,
serum CRP levels were related to concentrations of IL-6
(r = 0.333, p < 0.001), IL-8 (r = 0.125, p = 0.039), fibrino-
gen (r = 0.356, p < 0.001) and A1AT (r = 0.194, p < 0.001).
In our COPD patients, CRP and IL-6 were inversely
related to postbronchodilator FEV1 (% predicted). How-
ever, the contribution of systemic inflammation to lung
function decline is less clear. While crossectional studies
show that systemic inflammatory markers are inversely
related to lung function [6,13,25], a prospective evalua-
tion of lung function decline in a randomly selected pop-
ulation did not identify this negative effect over a 9-year
period [34].
Finally, we found that exercise tolerance, as assessed by
the distance walked in the 6-minute test was inversely
related to serum CRP, IL-6 and IL-8 levels. IL-6 is pro-
duced by contracting muscles and released into the
blood, acting as an energy sensor. When contracting
muscles are low in glycogen, IL-6 gene transcription is
increased and IL-6 is released to increase glucose uptake
and induce lipolysis [35]. When muscles are exposed to
oxidative stress, both IL-6 mRNA and IL-6 protein
expression are enhanced [35]. It is known that COPD
p a t i e n t s  w i t h  h i g h  p l a s m a  l e v e l s  o f  C R P  h a d  m o r e
Albumin Intercept 50.071 (1.165) 47.781-52.361 0.001
Age -0.066 (0.013) -0.092- -0.040 0.001
BMI 0.028 (0.030) -0.031-0.087 0.350
Smoker -0.083 (0.911) -1.873-1.707 0.928
Gender -0.759 (0.290) -1.329- -0.188 0.009
COPD group -0.299 (0.333) -0.955-0.356 0.370
Nitrites/nitrates† Intercept 1.636 (0.097) 1.445-1.828 0.001
Age -0.001 (0.001) -0.003-0.001 0.35
BMI -0.004 (0.002) -0.009-0.000 0.116
Smoker -0.007 (0.076) -0.157-0.143 0.926
Gender -0.079 (0.024) -0.127- -0.031 0.001
COPD group 0.059 (0.028) 0.004-0.114 0.034
* Main effects of factors and covariates included in the generalized linear model analysis. Smoker was defined as current or former smoker of 
> 10 packs-year (yes/no). COPD group effect was estimated versus reference group. † Parameter with logarithmic transformation.
Table 3: Significance of each multivariate model to estimate systemic biomarkers*. (Continued)Garcia-Rio et al. Respiratory Research 2010, 11:63
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Figure 3 Serum concentrations of systemic biomarkers in COPD patients and control subjects. Data are presented as mean adjusted for age, 
sex, pack-years of smoking and body-mass index (standard error of the mean). A logarithmic transformation was used for CRP and NOx. Abbreviations: 
CRP = C-reactive protein; TNF = tumor necrosis factor; IL = interleukin; A1AT = alpha-1 antitrypsin; NOx = nitrites/nitrates.
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impaired energy metabolism, increased disability and
more distress due to respiratory symptoms than patients
with normal CRP levels [35]. Moreover, the relation
between serum CRP levels and exercise tolerance seems
to be independent of other factors such as age, sex, and
smoking history [36]. Whether skeletal muscle dysfunc-
tion is a direct consequence of the systemic effects of the
COPD or an independent process that contributes to the
systemic inflammatory load of the disease, our results
indicate that systemic biomarker levels could indirectly
reflect the exercise capacity of these patients.
Strengths and weakness of the study
The strengths of this study include its population-based
design, the use of post-bronchodilator spirometry as
diagnostic criteria and the detailed characterization of
the participants which allowed us to investigate factors
associated with circulating biomarker levels. In addition
to the post-bronchodilator spirometric criteria confirm-
ing the existence of an irreversible obstruction, in our
never-smoker COPD patients there was evidence of the
existence of a particular exposure history that could sup-
port the diagnosis.
Although it has been reported that the fixed FEV1/FVC
ratio method results in a greater proportion of COPD
diagnoses than other alternative methods, especially in
the elderly, it still continues to be the criterion established
in the GOLD guidelines and is certainly the most widely
used in clinical practice. The current debate about LLN as
an alternative to the fixed ratio is based more on the
opinions of experts [37,38] than on the existence of clear
evidence. In this situation, the information provided by
the Cardiovascular Health Study is especially relevant,
demonstrating that a cohort of elderly subjects classified
as ''normal'' using the LLN but abnormal using the fixed
ratio were more likely to die and to have a COPD-related
hospitalization during an 11-year follow-up [39]. Thus, a
fixed FEV1/FVC ratio < 0.70 may identify at-risk patients,
even among older adults.
There are several potential limitations of our study
worth discussing. Firstly, our COPD patient sample does
not turn out to be necessarily representative of the COPD
regularly seen in clinical practice. Due to the design of the
present study, and to avoid the confusion by comorbidi-
ties, patients with several associated illnesses were
excluded from the analysis. This strategy probably
reduces differences between the two study groups, but it
assures a stricter evaluation of these. Secondly, there were
significant differences between COPD patients and refer-
ence subjects for anthropometric characteristics and
smoking status. These are consequences of the popula-
tion-based extraction of our study subjects and are partly
Table 4: Distribution of systemic biomarkers by severity of COPD according to GOLD criteria *.
Mild COPD
(n = 177)
Moderate COPD
(n = 128)
Severe COPD
(n = 19)
p
M a l e  ( % ) 6 7 . 88 2 . 08 4 . 2 0 . 0 1 2
Age (yr) 62 (54-70) 67 (58-73) † 70 (66-74) † 0.003
BMI (Kg/m2) 27.4 (4.7) 28.5 (4.7) 28.7 (6.4) 0.107
Smoking status 0.135
Never smoker 37.6 37.5 21.1
Former smoker 37.9 46.1 63.2
Current smoker 24.3 16.4 15.8
Smoking exposure (packs-year) 30 (20-47) 45 (30-60) ‡ 40 (22-54) 0.001
C-reactive protein (mg/l) 3.0 (2.0-5.0) 3.0 (2.0-6.0) 2.0 (2.0-12.0) ‡ 0.007
TNF-alpha (pg/ml) 10.0 (7.0-14.0) 11.0 (8.0-18.0) † 11.0 (5.0-14.0) 0.017
IL-6 (pg/ml) 1.9 (1.9-3.0) 1.9 (1.9-7.0) 3.0 (1.9-16.0) † 0.008
IL-8 (pg/ml) 2.0 (0.7-7.8) 2.0 (0.7-10.0) 7.0 (0.9-11.0) 0.323
Alpha-1 antitrypsin (g/l) 1.47 (1.27-1.72) 1.47 (1.32-1.73) 1.59 (1.38-1.83) 0.706
Fibrinogen (g/l) 3.46 (1.04) 3.63 (1.11) 3.73 (1.17) 0.305
Albumin (g/l) 45.36 (2.54) 45.41 (3.03) 44.67 (3.51) 0.571
Nitrites/nitrates (nmol/l) 26.3 (20.8-38.1) 23.3 (19.1-31.2) 27.1 (17.7-61.8) 0.048
* Values are mean (SD) or median (interquartile range) depending on the distribution. Abbreviations: TNF = tumour necrosis factor; IL = 
interleukin. Comparisons between groups by ANOVA with Bonferroni test: † p < 0.05 vs. mild COPD; ‡ p < 0.01 vs. mild COPD; p < 0.05 vs. 
moderate COPD; § p < 0.01 vs. moderate COPD.Garcia-Rio et al. Respiratory Research 2010, 11:63
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a reflection of the fact that some differences are likely
manifestations of the disease. Although the statistical
model aims to adjust for these possible confounding fac-
tors, the existence of some uncontrolled effects cannot be
excluded. And finally, this is a cross-sectional study, and
inference of causality is not possible. Our results could
also be affected by other drawbacks. Of the COPD
patients in our study, 23% were using inhaled corticoster-
oids. This could contribute to the underestimation of the
difference in systemic biomarkers between COPD
patients and control subjects. Nevertheless, the effect of
inhaled corticosteroids on inflammatory biomarkers is
still controversial. In patients with moderate to severe
COPD, it has been reported that one month of flutica-
sone did not reduce serum CRP or IL-6 levels [28]. Other
chronic conditions, such as chronic heart failure or dia-
betes, also appear to be associated with a similar low-
grade systemic inflammatory process [22]. Several studies
have described that these disorders are more frequent in
COPD patients and, therefore, might also contribute to
their proinflammatory state. Nevertheless, and in order
to analyze only the effect of COPD as an independent fac-
tor, we have carefully excluded these conditions from the
present study.
Conclusions
This study provides information about the population-
based distribution of some systemic biomarkers accord-
ing to lung function and BODE index, and reinforces the
e v i d e n c e  t h a t  C O P D  i s  i n d e p e n d e n t l y  a s s o c i a t e d  w i t h
low-grade systemic inflammation, with a different
inflammatory pattern than the one observed in healthy
subjects. In addition to its contribution to the extrapul-
monary effects of COPD, the intensity of the systemic
inflammation is directly related to the poorer quality of
life, airflow limitation and exercise intolerance observed
in COPD. These results emphasize the importance of car-
rying out multidimensional evaluations of COPD
patients, of interest to understanding the mechanisms
involved in COPD development and progression, as well
as for the management of individual patients.
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Figure 4 Relationship between serum concentrations of biomarkers and distance walked in 6-minutes in COPD patients. Abbreviations: CRP 
= C-reactive protein; IL = interleukin; r = Pearson's linear bivariate correlation coefficient.
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